Compare Stocks: AVR, TMDX, ATRC, and AXGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$53.03 -1.3%	$41.54	$25.36 ▼ $55.72	$2.73B	1.26	755,361 shs	1.60 million shs
AVR Anteris Technologies Global	$8.53 -1.0%	$8.87	$3.30 ▼ $11.06	$840.09M	1.8	611,739 shs	681,935 shs
AXGN AxoGen	$47.27 +1.2%	$45.36	$15.27 ▼ $52.91	$2.51B	1.16	782,813 shs	638,825 shs
TMDX TransMedics Group	$86.40 -2.1%	$81.41	$60.10 ▼ $156.00	$3.05B	1.9	605,019 shs	665,126 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	-1.30%	+0.84%	+27.35%	+86.66%	+46.86%
AVR Anteris Technologies Global	-1.04%	-0.70%	-4.80%	-8.38%	+83.84%
AXGN AxoGen	+1.24%	-2.13%	-1.97%	+11.59%	+187.88%
TMDX TransMedics Group	-2.12%	+2.50%	-2.27%	+17.41%	-20.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$53.03 -1.3%	$41.54	$25.36 ▼ $55.72	$2.73B	1.26	755,361 shs	1.60 million shs
AVR Anteris Technologies Global	$8.53 -1.0%	$8.87	$3.30 ▼ $11.06	$840.09M	1.8	611,739 shs	681,935 shs
AXGN AxoGen	$47.27 +1.2%	$45.36	$15.27 ▼ $52.91	$2.51B	1.16	782,813 shs	638,825 shs
TMDX TransMedics Group	$86.40 -2.1%	$81.41	$60.10 ▼ $156.00	$3.05B	1.9	605,019 shs	665,126 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	-1.30%	+0.84%	+27.35%	+86.66%	+46.86%
AVR Anteris Technologies Global	-1.04%	-0.70%	-4.80%	-8.38%	+83.84%
AXGN AxoGen	+1.24%	-2.13%	-1.97%	+11.59%	+187.88%
TMDX TransMedics Group	-2.12%	+2.50%	-2.27%	+17.41%	-20.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRC AtriCure	2.75	Moderate Buy	$52.00	-1.94% Downside
AVR Anteris Technologies Global	2.60	Moderate Buy	$16.00	87.57% Upside
AXGN AxoGen	2.75	Moderate Buy	$51.56	9.07% Upside
TMDX TransMedics Group	2.38	Hold	$124.18	43.73% Upside

Current Analyst Ratings Breakdown

Latest AVR, TMDX, ATRC, and AXGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	TMDX TransMedics Group	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/2/2026	ATRC AtriCure	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $64.00
8/31/2026	TMDX TransMedics Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/27/2026	ATRC AtriCure	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $60.00
8/26/2026	AVR Anteris Technologies Global	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	AXGN AxoGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	AXGN AxoGen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$60.00
8/24/2026	ATRC AtriCure	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/24/2026	ATRC AtriCure	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $55.00
8/19/2026	ATRC AtriCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/14/2026	AVR Anteris Technologies Global	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRC AtriCure	$534.53M	5.05	$0.31 per share	171.67	$9.89 per share	5.36
AVR Anteris Technologies Global	$1.91M	435.25	N/A	N/A	($0.01) per share	-853.00
AXGN AxoGen	$225.21M	11.28	N/A	N/A	$2.79 per share	16.94
TMDX TransMedics Group	$605.49M	4.93	$3.84 per share	22.48	$13.79 per share	6.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRC AtriCure	-$11.45M	$0.21	252.54	117.84	N/A	1.85%	2.34%	1.77%	11/4/2026 (Estimated)
AVR Anteris Technologies Global	-$94.14M	-$1.95	N/A	N/A	N/A	-4,619.27%	-77.69%	-67.99%	11/11/2026 (Estimated)
AXGN AxoGen	-$15.70M	-$0.68	N/A	945.40	N/A	-13.36%	-8.90%	-6.47%	11/4/2026 (Estimated)
TMDX TransMedics Group	$190.29M	$3.89	22.21	38.23	N/A	22.69%	15.88%	5.95%	11/4/2026 (Estimated)

Latest AVR, TMDX, ATRC, and AXGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026 TU	AVR Anteris Technologies Global	-$0.2073	-$0.30	-$0.0927	-$0.30	$1.50 million	$1.01 million
8/4/2026	Q2 2026	TMDX TransMedics Group	$0.4955	$0.44	-$0.0555	$0.41	$184.00 million	$189.95 million
7/29/2026	Q2 2026	AXGN AxoGen	$0.1214	$0.12	-$0.0014	-$0.03	$67.10 million	$69.73 million
7/23/2026	Q2 2026	ATRC AtriCure	-$0.0017	$0.18	+$0.1817	$0.18	$151.80 million	$153.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRC AtriCure	0.14	4.22	3.19
AVR Anteris Technologies Global	N/A	14.20	14.20
AXGN AxoGen	0.07	6.60	5.04
TMDX TransMedics Group	1.62	6.62	6.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRC AtriCure	99.11%
AVR Anteris Technologies Global	N/A
AXGN AxoGen	80.29%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
ATRC AtriCure	4.00%
AVR Anteris Technologies Global	4.50%
AXGN AxoGen	2.44%
TMDX TransMedics Group	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRC AtriCure	1,300	50.87 million	48.83 million	Optionable
AVR Anteris Technologies Global	138	97.46 million	93.07 million	N/A
AXGN AxoGen	450	53.76 million	52.45 million	Optionable
TMDX TransMedics Group	210	34.56 million	32.18 million	Optionable

AVR, TMDX, ATRC, and AXGN Headlines

Recent News About These Companies

TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of "Hold" from Brokerages

2 hours ago | americanbankingnews.com

TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Hold" by Brokerages

3 hours ago | marketbeat.com

TD Cowen Reaffirms "Buy" Rating for TransMedics Group (NASDAQ:TMDX)

4 hours ago | americanbankingnews.com

TransMedics Group's (TMDX) "Buy" Rating Reiterated at TD Cowen

September 8 at 10:35 AM | marketbeat.com

TransMedics: Slowing Growth Brings Its Valuation Into Question

September 8 at 6:53 AM | seekingalpha.com

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

September 7 at 3:03 PM | prnewswire.com

Jupiter Topco LLC Makes New Investment in TransMedics Group, Inc. $TMDX

September 6, 2026 | marketbeat.com

TransMedics Group, Inc. $TMDX Position Increased by Wellington Management Group LLP

September 5, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Acquires Shares of 17,159 TransMedics Group, Inc. $TMDX

September 5, 2026 | marketbeat.com

TransMedics Group, Inc. $TMDX Position Increased by FirstWave Capital Management LLC

September 5, 2026 | marketbeat.com

19,289 Shares in TransMedics Group, Inc. $TMDX Bought by Corient Private Wealth LP

September 5, 2026 | marketbeat.com

Legal & General Group Plc Invests $5.29 Million in TransMedics Group, Inc. $TMDX

September 4, 2026 | marketbeat.com

TransMedics Group, Inc. $TMDX Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 4, 2026 | marketbeat.com

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

September 3, 2026 | zacks.com

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

September 3, 2026 | zacks.com

Braidwell LP Has $40.50 Million Position in TransMedics Group, Inc. $TMDX

September 3, 2026 | marketbeat.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

September 2, 2026 | globenewswire.com

Empowered Funds LLC Purchases New Stake in TransMedics Group, Inc. $TMDX

September 2, 2026 | marketbeat.com

193,752 Shares in TransMedics Group, Inc. $TMDX Purchased by Bank of New York Mellon Corp

September 2, 2026 | marketbeat.com

Headlands Technologies LLC Purchases Shares of 24,599 TransMedics Group, Inc. $TMDX

September 1, 2026 | marketbeat.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

August 31, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVR, TMDX, ATRC, and AXGN Company Descriptions

AtriCure NASDAQ:ATRC

$53.03 -0.70 (-1.30%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$53.03 0.00 (0.00%)

As of 09/9/2026 07:30 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Anteris Technologies Global NASDAQ:AVR

$8.53 -0.09 (-1.04%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$8.54 +0.01 (+0.06%)

As of 09/9/2026 07:30 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

AxoGen NASDAQ:AXGN

$47.27 +0.58 (+1.24%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$47.35 +0.08 (+0.17%)

As of 05:13 AM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

TransMedics Group NASDAQ:TMDX

$86.40 -1.87 (-2.12%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$86.41 +0.01 (+0.01%)

As of 04:00 AM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVR, TMDX, ATRC, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVR, TMDX, ATRC, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVR, TMDX, ATRC, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVR, TMDX, ATRC, and AXGN Company Descriptions

AtriCure NASDAQ:ATRC

Anteris Technologies Global NASDAQ:AVR

AxoGen NASDAQ:AXGN

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVR, TMDX, ATRC, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVR, TMDX, ATRC, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVR, TMDX, ATRC, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVR, TMDX, ATRC, and AXGN Company Descriptions

AtriCure NASDAQ:ATRC

Anteris Technologies Global NASDAQ:AVR

AxoGen NASDAQ:AXGN

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools